Dean&Francis
ISSN 2959-6157

Brain-Computer Interface Based Cognitive Rehabilitation for Alzheimer's Diseases Patients

James Zijian Wang

James McKelvey School of Engineering, Washington University in St. Louis, St. Louis, USA
*Corresponding author: James.z.wang@wustl.edu

Abstract:

Alzheimer's Disease (AD) presents a significant challenge to healthcare systems worldwide, with its progressive cognitive decline impacting millions. This paper explores the potential of Brain-Computer Interface (BCI) based neurofeedback therapy as a novel approach to cognitive rehabilitation for AD patients. Traditional pharmacological interventions, though widely used, are limited by efficacy and side effects. Neurofeedback, leveraging real-time neural activity feedback, offers a non-invasive alternative, stimulating neuroplasticity and self-regulation of brain activity. The integration of BCI technology allows for personalized, adaptive therapy, responding to individual patient needs. The paper reviews the complex pathophysiology of AD, emphasizing the critical roles of amyloid-beta plaques and tau protein tangles in the progression of cognitive impairment. It delves into the mechanisms of neurofeedback, its clinical applications, and the combination of BCI with neurofeedback in treating AD. Preliminary findings suggest neurofeedback can stabilize or improve cognitive functions in AD patients, distinct from the typical decline. Despite these promising results, the overall efficacy of neurofeedback in AD treatment is not yet fully established. The approach remains under scrutiny, necessitating further rigorous research and large-scale clinical trials to validate its long-term benefits and optimal protocols. The paper concludes by emphasizing the need for extensive, interdisciplinary research, including longitudinal studies and standardized protocols, to fully realize and validate the therapeutic potential of BCI-enhanced neurofeedback in managing AD across various stages of the disease.

Keywords: Alzheimer's Disease; Brain-Computer Interface; Neurofeedback.

ISSN 2959-6157

1. Introduction

Alzheimer's Disease, along with other cognitive disorders, is one of the most serious and mysterious problems in human society. More importantly, as the global population ages, the prevalence of Alzheimer's disease is on the rise, underscoring the urgency for effective intervention strategies. The typical symptoms regarding these diseases or disorders are characterized by progressive degeneration of cognitive function (dementia), severely impacting memory, language, and executive abilities. Therefore, there are untold attempts to address this issue by alleviating symptoms or rehabilitating cognitive function. While these diseases cannot be eradicated, various methods have been developed to control and stabilize their symptoms. The traditional approach involves prescribing medication to patients to achieve these goals. However, this approach has serious drawbacks. The most significant is limited efficacy, with additional concerns including the risk of addiction, overdose, and invasiveness.

A relatively novel approach called neurofeedback (NF) treatment, thus, emerges in the public. It is a kind of biofeedback that can train new subjects' neural activity pattern. During this process, some representations (auditory, visual, or other) of neural activity is shown to the subjects so that they can self-regulate their neural activity in real time. The participants will be rewarded if they demonstrate patterns of interest. This approach not only bypasses disadvantages brought by medication but also indicates better performance in symptoms controlling. Moreover, it has the potential to enhance neuroplasticity, the brain's ability to reorganize and form new neural connections, which is often compromised in Alzheimer's disease.

NF treatment not only incorporates knowledge from psychology and neuroscience but also crucially relies on the use of Brain-Computer Interface (BCI). This cutting-edge technology enables researchers to both assess and modulate the neural activity of subjects, enhancing the effectiveness of NF treatment. This integration also allows for a more dynamic and interactive rehabilitation process, where patients can engage with their therapy through adaptive and responsive systems. By engaging patients in active cognitive tasks that promote the modulation of specific brainwave frequencies, BCIs can stimulate the dormant neural pathways and potentially restore or maintain cognitive functions. Furthermore, BCI offers the potential for personalized treatment tailored to each patient's specific condition, potentially surpassing the efficacy of generalized medication regimens.

2. Alzheimer's Disease Pathway

A progressive neurological illness that affects memory, learning, and behavior, Alzheimer's disease (AD) is marked by a slow deterioration in cognitive function. In order to address the issue, it is important to understand the pathway involved in AD development. Though there is not a consensus on the mechanism or pathway of AD and the root cause of the illness intricate and multifaceted, some pathological processes have been proposed for possible explanation.

One of the key pathological hallmarks of AD is the accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs), primarily composed of hyperphosphorylated tau proteins. These abnormal protein aggregates disrupt the neuronal cytoskeleton and synapses, the junctions between neurons that facilitate communication. Synaptic dysfunction and loss are directly linked to a decline in neuroplasticity, as they impair the brain's ability to form and modify connections, which is critical for learning and memory processes.

The cholinergic hypothesis of AD highlights the importance of the neurotransmitter acetylcholine (ACh) in cognitive function. A reduction in ACh levels due to increased acetylcholinesterase (AChE) activity is thought to contribute to memory deficits in AD. ACh plays a pivotal role in maintaining neuroplasticity by modulating synaptic transmission and facilitating long-term potentiation (LTP), a process associated with the strengthening of synaptic connections during learning. In AD, the decrease in ACh levels hampers LTP, thereby negatively affecting neuroplasticity.

Moreover, the hyperactivity of the N-methyl-D-aspartate (NMDA) receptors due to the accumulation of Aβ oligomers can lead to excitotoxicity, causing an excessive influx of calcium ions into neurons. This can trigger a cascade of cellular events that result in synaptic dysfunction and neuronal death, further impairing neuroplasticity. The NMDA receptor is crucial for synaptic plasticity, and its dysregulation in AD contributes to the deterioration of cognitive functions.

The sirtuin family of proteins, which are involved in neuronal survival and synaptic plasticity, are also affected in AD. Sirtuins are NAD+-dependent deacetylases that modulate gene expression and are thought to protect against neurodegeneration. Reduced sirtuin activity in AD has been linked to increased neuronal vulnerability and a decline in neuroplasticity.

Furthermore, the mammalian target of rapamycin (mTOR) pathway, which is essential for synaptic plasticity and learning, is also disrupted in AD. Hyperactivity of mTOR signaling can lead to increased translation of tau protein, contributing to tau pathology and impairing synaptic function.

Alzheimer's disease (AD) impairs cell death, neural transmission, and neuroplasticity through a complex interaction of pathogenic processes. The buildup of toxic proteins, loss of synaptic connections, and dysfunctional synapses are hallmarks of the disease's course, all of which impair the brain's capacity for adaptation, learning, and memory. The goal of current therapy approaches is to address these pathogenic variables in order to reduce symptoms and maybe even delay the course of the disease [1][2].

3. Neurofeedback Therapy

3.1 Mechanism of Neurofeedback

Neurofeedback therapy is a form of biofeedback that operates on the principle of self-regulation of neural activity. It involves measuring brain activity in real-time and providing visual, auditory, or other forms of feedback to the participant, allowing them to learn how to influence their own brain function. This process is based on the concept that voluntary control can be gained over specific neural substrates, which are the underlying neural processes related to particular behaviors or pathological conditions.

The mechanism of neurofeedback therapy begins with the use of various neuroimaging techniques such as electroencephalography (EEG), functional magnetic resonance imaging (fMRI), and others to monitor brain activity. These techniques provide a real-time representation of the brain's electrical or metabolic activity, which is then translated into a format that the participant can understand and respond to, such as a changing image or sound.

During a neurofeedback session, the participant is trained to recognize how their thoughts, emotions, or behaviors correspond to changes in their brain activity as represented by the feedback. Over time, through repetition and practice, the participant learns to self-regulate their brain activity by associating the feedback with the desired change in brain function. This learning process is thought to involve neuroplasticity, the brain's ability to reorganize itself by forming new neural connections.

For instance, in the context of ADHD, neurofeedback therapy might focus on reducing excessive low-frequency EEG oscillations typically observed in individuals with the condition. By learning to control these oscillations, participants may experience improvements in ADHD symptoms. Similarly, in stroke rehabilitation, neurofeedback could be used to enhance motor function by modulating the activity of sensorimotor areas.

The therapy's effectiveness is believed to rely on several factors, including the participant's ability to understand and utilize the feedback, the specificity of the neural targets being regulated, and the persistence of these changes over time. Neurofeedback is considered a form of endogenous neural stimulation, as the physiological consequences result from the individual's self-manipulation of their neural activation.

Moreover, neurofeedback is not just limited to surface brain activity but can also modulate deeper brain structures and neural oscillations, providing a comprehensive approach to influencing brain function. The therapy's goal is to facilitate long-lasting changes in brain activity that translate into improvements in behavior and symptoms related to various neurological and psychiatric conditions [3][4].

3.2 Application of NF Treatment

One of the primary applications of neurofeedback is in the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Research has shown that children with ADHD often exhibit abnormal EEG patterns, particularly increased slow-wave activity in the form of theta and delta bands. Neurofeedback therapy aims to reduce these abnormal patterns by training the brain to produce more normalized frequencies. Through repeated sessions, patients learn to modulate their brainwave activity, which corresponds to improvements in attention and reduction in hyperactive and impulsive behaviors.

Another significant application area is in the rehabilitation of stroke patients. Post-stroke, many individuals experience motor impairments due to damage to specific brain regions. Neurofeedback can be utilized to enhance the brain's self-repair mechanisms by reinforcing desired neural activity patterns. For instance, patients may be trained to increase activity in the motor cortex, which can lead to improved motor function. This approach is particularly promising when combined with other rehabilitation strategies such as physiotherapy.

Neurofeedback has also been explored in the treatment of anxiety and mood disorders. By training individuals to regulate their alpha and beta brainwaves, neurofeedback may help reduce anxiety symptoms and enhance mood stability. The approach is based on the premise that certain brainwave patterns are associated with relaxed and focused states, and by learning to produce these patterns voluntarily, individuals can achieve a greater sense of control over their emotional states.

Moreover, the application of neurofeedback extends to the realm of cognitive enhancement. Healthy individuals and those with mild cognitive impairments can benefit from training aimed at optimizing brain function. For example, increasing the coherence of brain activity across different

ISSN 2959-6157

regions can lead to improved working memory, cognitive flexibility, and overall cognitive performance.

The effectiveness of neurofeedback treatment is subject to several factors. These include the individual's ability to learn the self-regulation of brain activity, the specificity of the neurofeedback protocol to the disorder, and the motivation and commitment of the patient. Additionally, the therapeutic alliance between the patient and the clinician, the use of appropriate technology, and the integration of neurofeedback into a comprehensive treatment plan are crucial for achieving optimal outcomes.

The treatment represents a promising non-pharmacological intervention for a variety of neurological and psychiatric conditions. Its application lies in the potential to harness the brain's plasticity to promote healing, enhance cognitive functions, and improve the quality of life for individuals affected by these disorders. As research continues to unravel the complexities of brain function and the mechanisms underlying neurofeedback, it is likely that this treatment will become an increasingly integral part of clinical practice [5].

3.3 Neurofeedback's application in Alzheimer's Disease

In the context of AD, neurofeedback treatment is based on the quantified electroencephalogram (qEEG), a method that measures electrical activity in the brain. Patients with AD typically exhibit an increased amount of theta activity and a decrease in alpha and beta activity compared to healthy elderly individuals. The neurofeedback process involves training the patient to self-regulate their brainwave patterns, specifically aiming to decrease theta activity and increase alpha and beta activity, which are associated with improved cognitive functioning.

The study highlighted in the document presents preliminary findings on the effectiveness of neurofeedback on cognitive functioning in AD patients. Ten patients diagnosed with AD, aged between 61 and 90 years, were provided with neurofeedback training. The treatment was individualized based on each patient's qEEG profile, and the training involved sessions twice a week for fifteen weeks, totaling thirty sessions. During these sessions, patients received real-time feedback on their brainwave activity, allowing them to learn to modulate their neural activity.

The Cambridge Cognitive Examination (CAMCOG) test was used to assess cognitive functioning before and after the neurofeedback treatment. The results, analyzed using a reliable change index (RCI), indicated that patients who underwent neurofeedback treatment maintained stable cognitive functions. Notably, improvements were observed in memory after the treatment, and other cognitive functions remained stable. Additionally, enhancements in the recall of information and recognition were noted.

The findings suggest that neurofeedback could be a potential intervention to stabilize or slow down the cognitive decline in AD patients. The treatment's mechanism is believed to involve the reinforcement of desirable brain activity and the inhibition of undesirable activity, leading to changes in brain wave patterns that correspond to improved cognitive performance.

It is important to consider that neurofeedback treatment is not a one-size-fits-all approach. The individualized training protocols are crucial, given the heterogeneity in EEG patterns associated with AD. Furthermore, the study's results should be interpreted with caution due to its small sample size and the lack of a control group.

The application of neurofeedback treatment in AD patients is a promising area of research that warrants further investigation. High-quality randomized controlled trials are needed to confirm the effectiveness of neurofeedback in treating AD and to understand its potential role in the therapeutic landscape for this debilitating condition. The future of neurofeedback in AD treatment may lie in its ability to harness the brain's plasticity, offering a non-pharmacological approach to support cognitive function and potentially improve the quality of life for patients [6].

4. Combination of Brain-Computer Interface and Neurofeedback Therapy

The combination of Brain-Computer Interface (BCI) technology with Neurofeedback (NF) treatment represents an innovative approach in the field of neurorehabilitation and cognitive training. This synthesis leverages the direct measurement of brain activity through BCI with the self-regulation training of NF to create a powerful tool for managing and improving brain function. Here, this paper analyze how BCI concepts are integrated into NF treatment.

At the core of BCI technology is the ability to acquire, process, and interpret brain signals in real-time. This capability is crucial for NF treatment, as it allows for the immediate provision of feedback to the user regarding their brain activity. For instance, if the goal is to increase the power of alpha waves, which are associated with relaxation, the BCI system would detect these waves and provide feedback through visual or auditory cues when the user successfully increases alpha activity. This real-time aspect is a significant advancement over traditional NF methods, which often rely on delayed feedback mechanisms.

BCI systems are adept at processing complex brain signals, extracting relevant features, and translating them into actionable information. In the context of NF treatment, this involves identifying specific brainwave patterns or frequencies that correspond to the desired cognitive or behavioral state. For example, beta waves (13-30 Hz) are linked to alertness and concentration, and a NF treatment aimed at improving focus might target these frequencies. The BCI system processes the EEG data to isolate beta wave activity and provides feedback to the user, helping them to modulate their brain activity towards the desired state.

One of the key strengths of combining BCI with NF is the ability to create customized feedback mechanisms tailored to the individual's needs. BCI systems can be programmed to respond to specific changes in brain activity, providing feedback that is both relevant and engaging for the user. This personalization is essential for effective NF treatment, as it ensures that the training is targeted and that the user is actively involved in the process. For example, a user with ADHD might receive feedback that encourages the suppression of theta waves (associated with inattention) and the enhancement of beta waves (associated with focus), using a combination of visual, auditory, and tactile cues.

BCI technology can also be integrated with assistive devices to provide physical feedback, which can be particularly beneficial in motor rehabilitation. For instance, a BCI system might be connected to a robotic exoskeleton, allowing a patient with limited mobility to control the device through their thoughts. This not only provides a physical output for the NF training but also offers tangible, real-world benefits for the patient. The feedback from the device's movement can reinforce the NF training, helping the patient to associate specific brainwave patterns with the control of the device.

EEG-based BCI intervention could also provide insights into the mechanisms of neuroplasticity during upper limb recovery by offering feedback to the brain. BCI-based neurofeedback training has shown progress in improving attention and alertness in patients with cognitive diseases like ADHD. This is achieved by focusing on reducing the theta/beta rhythm ratio or enabling self-regulation of slow cortical potentials (Shown in Figure 1).



Fig. 1 Neurofeedback Pathway [7]

Despite the significant potential of BCI-NF integration, there are challenges to be addressed. These include the need for more research to establish standardized protocols, the development of more user-friendly systems, and the need to make this technology more accessible and affordable. Future developments may include the use of advanced algorithms for signal processing, the integration of machine learning to improve the personalization of NF treatments, and the exploration of new feedback modalities to enhance user engagement and outcomes [7-9].

5. Conclusion

In conclusion, neurofeedback therapy emerges as a beacon of hope in the realm of Alzheimer's disease (AD) treatment, offering a non-invasive and personalized approach

ISSN 2959-6157

to manage the symptoms and potentially slow cognitive decline. The advent of Brain-Computer Interface (BCI) technology further amplifies the potential of neurofeedback, allowing for more dynamic and responsive therapeutic interventions. The synergy between neurofeedback and BCI presents an exciting frontier in AD research, with the capacity to tailor treatments to the unique neural signatures of individual patients.

However, despite the promising nature of neurofeedback and the innovative integration with BCI, our understanding of AD's intricate pathological pathways remains incomplete. The heterogeneity of the disease and the multifactorial mechanisms at play complicate the picture, making it challenging to pinpoint the precise sequence of events that lead to cognitive dysfunction. Current studies exploring the efficacy of neurofeedback in conjunction with BCI are still in nascent stages, with results that are suggestive yet not conclusive enough to establish clinical recommendations for widespread use.

Extensive research is urgently needed to advance our understanding and fully harness the therapeutic potential of neurofeedback and BCI. Future studies should aim to include larger and more diverse patient populations, accounting for variables such as age, genetic background, and disease severity. Rigorous, long-term clinical trials are essential to evaluate the safety, efficacy, and durability of neurofeedback-BCI interventions in real-world settings.

The road to realizing the full potential of BCI and neurofeedback in the treatment of AD is ultimately paved by a dedication to scientific research and interdisciplinary cooperation. The possibility of a more successful, individualized treatment strategy becomes more real as people learn more about the intricacies of AD and advance our technical capabilities, providing a glimmer of hope for people afflicted by this terrible illness.

References

[1] Ramachandran A. K., et al. Neurodegenerative Pathways in Alzheimer‘s Disease: A Review. Current Neuropharmacology, 2021, 19(5): 679-692.

[2] Burns A., et al. Progression of cognitive impairment in Alzheimer‘s disease. Journal of the American Geriatrics Society, 1991, 39(1): 39-45.

[3] Sitaram R., et al. Closed-loop brain training: the science of neurofeedback. Nature Reviews Neuroscience, 2017, 18(2): 86-100.

[4] Niv S. Clinical efficacy and potential mechanisms of neurofeedback. Personality and Individual Differences, 2013, 54(6): 676-686.

[5] Jeunet C., et al. Using Recent BCI Literature to Deepen our Understanding of Clinical Neurofeedback: A Short Review. Neuroscience, 2018, 378: 225-233.

[6] Luijmes R. E., et al. The effectiveness of neurofeedback on cognitive functioning in patients with Alzheimer‘s disease: Preliminary results. Neurophysiologie Clinique = Clinical Neurophysiology, 2016, 46(3): 179-187.

[7] Zhuang M., Wu Q., et al. State-of-the-art non-invasive brain-computer interface for neural rehabilitation: A review. Journal of Neurorestoratology, 2020, 8(1): 12-25.

[8] Marzbani H., Marateb H. R., Mansourian M. Neurofeedback: A Comprehensive Review on System Design, Methodology and Clinical Applications. Basic and Clinical Neuroscience, 2016, 7(2): 143-158.

[9] Carelli L., et al. Brain-Computer Interface for Clinical Purposes: Cognitive Assessment and Rehabilitation. BioMed Research International, 2017, 2017: 169520.